I. Krakowski

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 727 citations

Androgen-deprivation Therapy, Urology, Genitourinary Cancer +7

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly et al. · European Urology · 2015 · 454 citations

Urology, Genitourinary Cancer, Getug-afu15 Trial +7

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier et al. · The Lancet Oncology · 2015 · 236 citations

Urology, Getug 12, Genitourinary Cancer +8

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

B Chevallier, P. Fumoleau, Pierre Kerbrat et al. · Journal of Clinical Oncology · 1995 · 222 citations

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model

Gwénaëlle Gravis, Jean‐Marie Boher, Karim Fizazi et al. · European Urology · 2014 · 128 citations · Full text

Prognostic Factors, Urology, Genitourinary Cancer +6